Despite improvements in percutaneous coronary artery intervention (PCI), coronary artery bypass grafting (CABG) remains the gold standard therapy for the majority of patients with multivessel coronary artery disease. This position has been corroborated by the results of the SYNTAX trial (Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery), which favored CABG over PCI especially in patients with advanced disease involving multiple territories, and a recent meta-analysis performed by Benedetto et al,¹ where CABG was compared with PCI with drug-eluting stents (DES-PCI) in 4563 patients. The results showed that, compared with CABG, DES-PCI resulted in a 50% relative increase in the risk for death, a 200% increased risk for myocardial infarction, and a 250% increased risk for repeat revascularization at 3.4 years after revascularization.